Johnson & Johnson Gets FDA Approval for Non-Small Cell Lung-Cancer Treatment

By Connor Hart

Johnson & Johnson said the Food and Drug Administration approved its treatment of locally-advanced or metastatic non-small cell lung cancer for adults.

The treatment, called Rybrevant, has been approved in combination with standard of care chemotherapy for patients with certain conditions, the New Jersey healthcare company said.

The approval is based on results from a Phase 3 study evaluating the efficacy and safety of Rybrevant in combination with chemotherapy for the treatment of adult patients with specific conditions, which showed the treatment in combination with chemotherapy reduced the risk of disease progression or death by 52% compared with chemotherapy alone.

"Patients need and deserve effective, targeted approaches across all lines of therapy," Vice President of Clinical Development Kiran Patel said. "With Rybrevant-based regimens, we are bringing potential new standards of care to the nearly 30,000 patients diagnosed with epidermal growth factor receptor-mutated non-small cell lung cancer in the United States each year."

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

September 19, 2024 19:35 ET (23:35 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.